Drugs / SY-201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05370495 | Jul 2022 → Mar 2023 | dry eye syndrome | Seinda Pharmaceutical Guangzhou Corporation | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SY-201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05370495 ↗ |